List of Next-Gen Sequencing Companies in New York - 14

The Genomics Core serves the Einstein scientific community by providing a broad range of services, utilizing current and emerging nucleic acid technologies. Single-cell assays, MPS, Microarrays, real-time PCR, Sanger sequencing and assay automation are available. The Core provides a number of technologies for genotyping DNA from humans or model organisms, varying from SNP (single nucleotide polymorphism) typing to targeted sequencing for variant discovery.

AptaMatrix is a privately held, start-up biotechnology company headquartered in Syracuse, New York. The company's focus is to accelerate the rate of aptamer discovery using its patent pending High Throughput Screening of Aptamers (HTSA) approach in addition to developing its novel AlloSwitch™ sensor technology capable of a) creating rapid diagnostic tools for detection of chemical and biological targets, and b) leveraging this diagnostic platform for drug discovery applications. AlloSwitches™, have demonstrated the ability to transduce molecular recognition of biological targets into a real-time (seconds) optical signal for identifying environmental and terrorist released contaminants in liquid systems. HTSA and AlloSwitch solutions are built on patented biotechnology based on years of leading-edge biological research and industry partnerships at Syracuse University. The HTSA approach leverages the high throughput capabilities of deep-sequencing technology. All sequencing activity is managed by our Genomics Division and conducted on our Illumina GAIIx platforms. Data analysis is supported by our in-house bioinformatics team. In addition to supporting internal research and development, our genomics division actively supports both academic and commercial deep-sequencing projects.

Basepair is a next generation bioinformatics company. Through a combination of intuitive interfaces and modern architecture we are reimagining what a commercial platform can deliver to R&D organizations. We're on a mission to make genomic data analysis & visualization more accessible to a broader range of scientists so that the promise of precision medicine can become a reality. One of the biggest challenges preventing this now arguably lies not with how the data gets generated and processed, but who is able to perform the analysis and understand what the resulting data means. Limiting this work to a select few, whether through choice or more often because of technology restrictions, especially for routine analyses, leads to reduced efficiency in R&D teams, longer times to market for assay manufacturers and increased turnaround times in clinical settings. Unlike other more traditional alternatives, our philosophy is not to ask bioinformaticians to change the way they work by having to build workflows on our platform. Instead, once they are built and ready for sharing or production settings, Basepair can significantly improve and accelerate both scaling & deployment to colleagues, collaborators and customers wherever they happen to be in the world. To do this in a way that is adapted to the dynamics of the market today, we believe a bioinformatics platform needs to: 1) Leverage the compute and storage resources in a third party cloud account without the requirement of installing inside an organization's vpc 2) Facilitate the bundling of analysis with the sale of a kit or assay through easy white labeling and tokens/coupons 3) Support ever increasing sample volumes and application areas through an extensible architecture that scales to millions of records, enables complete sample provenance and reduces cloud costs Introducing Basepair…bioinformatics reinvented.

CD Genomics is aiming at providing the research community with high quality Next Generation Sequencing, high throughput microarray services. Due to the demand for our services has being increased; CD Genomics has already updated its technology platform to mainstream NGS and microarray instruments. At present, our senior bioinformaticians have ever viewed more than ten thousands of trace files and accumulated abundant experience with our Illumina HiSeq2000/2500, Illumia Miseq, Ion Torrent PGM, PacBio RS and ABI 3730/3730XL analyzers. We continue to work hard to offer you the same dependable services to pharmaceutical and biotech companies, as well as academia and government agencies for the purpose of satisfying all your sequencing or array needs. In 2007, CD Genomics has expanded its services to molecular biology research and its development needs. We have become a service provider in sequencing, microarray analysis, library construction and genotyping. Our progress could not be achieved without our large group of client's support. Through nearly ten year's hard working and depend on our professional work team, we are proud of satisfying the needs of our clients both at home and abroad, which across more than 50 countries and districts. We always devote ourselves to providing you with the best and professional service.

At Cerba Research we provide world-class clinical research to help life science companies successfully develop the predictive and precision medicines of the future and help people live healthier lives. We are committed to delivering the next generation of healthcare by transforming research and advancing health together. We support you with industry-leading excellence in oncology, virology, vaccine development, immunology, and cell and gene therapy, together with world-class deep specialty testing, from next generation sequencing to flow cytometry, molecular diagnostics, IHC & and spatial Omics, and bioinformatics. We are committed to helping you deliver the next generation of human-centric healthcare, by transforming research, and advancing health together. Uniquely, we combine the experience of specialty laboratories with the global reach of a central lab. We have a worldwide network of 1000 labs, hold data from over 85 million patients across five continents, and have the ability to sequence 1000-plus whole human genomes per week. This unparalleled approach to patient data gives you the opportunity to have one partner for all your test services, with consistent access and support across all clinical trial phases.

Creative Genomics(CG) specializes in providing the services of DNA sequencing, genotyping and library construction in the global market. Our state-of-the-art sequencers including ABI3730xl, Roche 454 GS-FLX System and Illumina Solexa 1G Genome Analyzer make our customer-oriented DNA sequencing services to stand out with efficiency, reliability and flexibility. Coupled with a variety of high definition genotyping platforms such as Illumina BeadStation 500, Beadxpress and Sequenom, a full range of services from whole genome scans to targeted SNP genotyping can be provided with a high turnover rate. In addition, theyhave professional team members with extensive experience in library construction. Above all these, an in-house Laboratory Information Management System (LIMS) as well as manual basecalling by senior bioinfomaticians ensuresservices with the highest quality.

Gencove creates high-volume, cost-sensitive sequencing software-as-a-service to help academic, agriculture, biotech, diagnostic, and pharmaceutical companies get all the genomic information they need to make life-saving discoveries.

At Kallyope, we focus on big health challenges that matter to patients and families. We aim to discover and develop effective, easy to use, and well-tolerated oral agents addressing metabolic, neurological, and gastrointestinal diseases. Inside every human body is a complex, unexplored network of metabolic, neurological, and gastrointestinal interconnections. Our scientists are unlocking the mysteries of this network to develop oral therapies for obesity and diabetes; neurological disorders, including migraine; and gastrointestinal disease, including celiac disease. Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development. Together, we are leveraging multiple sophisticated technologies and internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health.

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing.

PAVmed (NASDAQ: PAVM) is a highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation.

Microfluidics for Molecular DiagnosticsCOVID-19: (12/2020) EUA for COVID-19™ MDx Assay

The Integrated Genomics Operation (IGO) at Memorial Sloan Kettering (MSK) is a collaborative core facility dedicated to generating high-quality genomics data for basic, translational, and clinical research projects. The core is focused on Illumina Next-Generation Sequencing (NGS) while also providing comprehensive genomics services including pathological review of tissue samples, fragment analysis, Sanger sequencing, and much more.

Stony Brook Medicine expresses our shared mission of research, clinical care and education – a mission embraced by our faculty, staff, researchers, and students. It is the embodiment of everything we do on behalf of the health of patients – not only here in our community, but also in the region and worldwide. Stony Brook Medicine comprises five Health Sciences schools — Renaissance School of Medicine, School of Dental Medicine, School of Health Technology and Management, School of Nursing and School of Social Welfare — as well as Stony Brook University Hospital, Stony Brook Southampton Hospital, Stony Brook Eastern Long Island Hospital, Stony Brook Children’s Hospital and more than 200 community-based healthcare settings throughout Suffolk County. Our health sciences schools work in tandem with our research and clinical care teams to deliver the best ideas in medicine to patients. As an academic medical center, we are all about ideas. Creating them. Nurturing them. Protecting them. Challenging them. Improving them. Teaching them to others. And most importantly of all, delivering them to patients and their families – sooner, smarter and better. An “idea” can be a new treatment protocol, best practices, a bright new researcher we’ve brought in from another institution, the convenience of an outpatient clinic, or simply a more user-friendly way to access our medical care. Ideas drive us, they thrive here, and we are committed to bringing more of them to our patients than anyone else.

At TRACER we are specialized in first-in-human studies with the use of nuclear and optical molecular imaging techniques. By labeling an antibody, small molecule, peptide, nanoparticle, protein, or any other compound of interest with a fluorescent dye or a radionuclide, fast in human data can be obtained with an indication of the potential efficacy of the novel drug, even before the classical phase 1-3 clinical trials. This can lead to a more efficient and less costly drug development process. We assist our sponsors in the labeling of their lead compounds and execute first-in-human studies to visualize and quantify the biodistribution and pharmacokinetics of the compound. With this information a “ go/no-go” decision can be made before the compound proceeds to the next phase in clinical development where costs are larger and time is valuable. Early in-human studies are approved by the EMA and FDA through the so-called principle of microdosing. It allows you to often skip (large) animal models and go straight into the patient population.